Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.

Date publication

janvier 2018

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine

Tous les auteurs :
Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Antoni L, Lukac M, Van Sanden S, Pissart G, Reid A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30116592

Résumé

Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are commonly prescribed for metastatic castration-resistant prostate cancer (mCRPC). Data comparing their effects on patient-reported outcomes (PROs) from routine clinical practice are limited.

Mots clés

abiraterone acetate, enzalutamide, metastatic castration-resistant prostate cancer, patient-reported outcomes

Référence

ESMO Open. 2018 ;3(5):e000397